AT-7519

DB08142InvestigationalSmall molecule

AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.

Mechanism: AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression.
Curator reviewed
Primary indication: Investigated for use/treatment in leukemia (unspecified), lymphoma (unspecified), myelodysplastic syndrome, and solid tumors.Curator reviewed
Formula / weight: C₁₆H₁₇Cl₂N₅O₂ · 382.244 g/mol (avg)
Code names: AT-7519

Resolves to

Compound

UNIIX1BF92PW9TCAS844442-38-2ChEMBLCHEMBL445813ChEBI91326PubChem11338033

Structure

InChIKeyOVPNQJVDAFNBDN-UHFFFAOYSA-NSMILESClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1

Targets

P24941CDK2P06493CDK1

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with AT-7519, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account